JAMA Editors' Summary From the JAMA Network: JAMA Research of the Year With Editor in Chief Kirsten Bibbins-Domingo
Dec 26, 2025
Kirsten Bibbins-Domingo, a physician-scientist and Editor-in-Chief of JAMA, joins Jennifer Abbasi to delve into groundbreaking research from the past year. They explore the Laryngostat trial that successfully reduced blood pressure in treatment-resistant hypertension. Kirsten also discusses the promising results of GLP-1s in heart failure, a shingles vaccine's link to lower dementia risk, and a hepatitis B vaccine trail in HIV patients. Plus, they highlight lifestyle interventions that may boost cognition in older adults and the implications of a new trial on transfusion thresholds.
AI Snips
Chapters
Transcript
Episode notes
Research Mirrors Hot Clinical Trends
- JAMA's selected studies reflect hot research areas and clinically important conditions like cardiology and GLP-1 therapies.
- They also showcase diverse, innovative methods that can influence practice and public health.
Real-World Data Complements Trials
- A clinical-trial-emulation using real-world data can complement randomized trials for GLP-1 drugs.
- Large, diverse observational cohorts give clinicians more confidence about therapy effects.
Quasi-Experimental Vaccine Design
- Quasi-experimental designs reduce healthy-vaccinee bias in vaccine–dementia studies.
- Using eligibility cutoffs (birth date) helps create comparable groups for observational inference.